HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 63, Number 7, October 12, 2004 Data Supplement Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in Neurology Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carroll, C. B. Articles by Zajicek, J. P. Search for Related Content PubMed PubMed Citation Articles by Carroll, C. B. Articles by Zajicek, J. P. Related Collections Parkinson's disease/Parkinsonism All Clinical trials Clinical trials Randomized controlled (CONSORT agreement)

Cannabis for dyskinesia in Parkinson disease

A randomized double-blind crossover study

From the Department of Neurology (Drs. Carroll, Parkin, and Hobart, and C. Wroath), Derriford Hospital, Plymouth; Peninsula Medical School (Drs. Zajicek, Teare, and Fox), University of Plymouth; Division of Neurosciences and Psychological Medicine (Drs. Bain and Liu), Charing Cross Campus, Imperial College London; Oxford Movement Disorders Group (C. Joint), Department of Neurology, Radcliffe Infirmary, Oxford; and School of Mathematics and Statistics (Dr. Wright), University of Plymouth, UK.

Address correspondence and reprint requests to Dr. Camille Carroll, Room N16 ITTC Building, Tamar Science Park, Plymouth, UK PL6 8BX; e-mail: cbc{at}doctors.org.uk

Background: The long-term treatment of Parkinson disease (PD) may be complicated by the development of levodopa-induced dyskinesia. Clinical and animal model data support the view that modulation of cannabinoid function may exert an antidyskinetic effect. The authors conducted a randomized, double-blind, placebo-controlled crossover trial to examine the hypothesis that cannabis may have a beneficial effect on dyskinesia in PD.

Methods: A 4-week dose escalation study was performed to assess the safety and tolerability of cannabis in six PD patients with levodopa-induced dyskinesia. Then a randomized placebo-controlled crossover study (RCT) was performed, in which 19 PD patients were randomized to receive oral cannabis extract followed by placebo or vice versa. Each treatment phase lasted for 4 weeks with an intervening 2-week washout phase. The primary outcome measure was a change in Unified Parkinson’s Disease Rating Scale (UPDRS) (items 32 to 34) dyskinesia score. Secondary outcome measures included the Rush scale, Bain scale, tablet arm drawing task, and total UPDRS score following a levodopa challenge, as well as patient-completed measures of a dyskinesia activities of daily living (ADL) scale, the PDQ-39, on-off diaries, and a range of category rating scales.

Results: Seventeen patients completed the RCT. Cannabis was well tolerated, and had no pro- or antiparkinsonian action. There was no evidence for a treatment effect on levodopa-induced dyskinesia as assessed by the UPDRS, or any of the secondary outcome measures.

Conclusions: Orally administered cannabis extract resulted in no objective or subjective improvement in dyskinesias or parkinsonism.

Received December 24, 2003. Accepted in final form June 1, 2004.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the October 12 issue to find the title link for this article.

Related articles in Neurology:

October 12 Highlights

Neurology 2004 63: 1146-1147. [Full Text]  

This article has been cited by other articles:

				T. Wang MSc, J.-P. Collet PhD MD, S. Shapiro PhD, and M. A. Ware MBBS MSc Adverse effects of medical cannabinoids: a systematic review Can. Med. Assoc. J., June 17, 2008; 178(13): 1669 - 1678. [Abstract] [Full Text] [PDF]

				R. Katzenschlager, A. Schrag, A. Evans, A. Manson, C. B. Carroll, D. Ottaviani, A. J. Lees, and J. Hobart Quantifying the impact of dyskinesias in PD: The PDYS-26: A patient-based outcome measure Neurology, August 7, 2007; 69(6): 555 - 563. [Abstract] [Full Text] [PDF]

				E. Benarroch Endocannabinoids in basal ganglia circuits: Implications for Parkinson disease Neurology, July 17, 2007; 69(3): 306 - 309. [Full Text] [PDF]

				H. D. Burns, K. Van Laere, S. Sanabria-Bohorquez, T. G. Hamill, G. Bormans, W.-s. Eng, R. Gibson, C. Ryan, B. Connolly, S. Patel, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor PNAS, June 5, 2007; 104(23): 9800 - 9805. [Abstract] [Full Text] [PDF]

				J. W. McSherry, C. B. Carroll, J. Zajicek, L. Teare, and P. Bain Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study Neurology, March 22, 2005; 64(6): 1100 - 1100. [Full Text] [PDF]

				A. Kofalvi, R. J. Rodrigues, C. Ledent, K. Mackie, E. S. Vizi, R. A. Cunha, and B. Sperlagh Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis J. Neurosci., March 16, 2005; 25(11): 2874 - 2884. [Abstract] [Full Text] [PDF]

Correspondence: